-
Mashup Score: 64Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial - 10 hour(s) ago
Pembrolizumab in combination with bevacizumab was more efficacious than pembrolizumab monotherapy, with manageable toxicities in platinum-resistant nasopharyngeal carcinoma. If validated in a phase 3 trial, the combination therapy could be a new standard of care in this population of patients.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62
Pembrolizumab in combination with bevacizumab was more efficacious than pembrolizumab monotherapy, with manageable toxicities in platinum-resistant nasopharyngeal carcinoma. If validated in a phase 3 trial, the combination therapy could be a new standard of care in this population of patients.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Randomized phase II study @TheLancetOncol shows that adding bevacizumab to pembrolizumab in previously treated nasopharygeal carcinoma improves RR (58.3% vs 12.5%) and significantly increased PFS to 13.8m from 1.6m: HR 0.25! #NPC https://t.co/B9Kr0DrPuu
-
-
Mashup Score: 0Three decades of progress in nasopharyngeal cancer - 1 year(s) ago
Tailored management for high-risk locoregional disease, with more effective immunotherapy combinations are key areas
Source: dailyreporter.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO23:After recent advancements in #nasopharingeal #CancerManagement, due to #immunotherapy and an effective #biomarker, what’s next for #NPC? Anthony Chan: treating patients w/ post-treatment residual #EBV DNA is an issue #ESMODailyReporter 👉 https://t.co/xNMCMhmQk6 https://t.co/6u2uzcmCwL
-
-
Mashup Score: 0Comprehensive maturity of nuclear pore complexes regulates zygotic genome activation - 2 year(s) ago
Experiments in zebrafish indicate that nuclear pore complex (NPC) maturation serves as a molecular timer of zygote genome activation, a key part of the oocyte-to-embryo transition during vertebrate development. Increased size and complexity of NPCs leads to increased nuclear transport of maternal transcription factors, allowing transcription factors to reach thresholds that initiate zygotic…
Source: CellCategories: Healthcare Professionals, Latest HeadlinesTweet-
NICE: Comprehensive maturity of #nuclearpore complexes regulates zygotic genome activation https://t.co/dQfx4l5cSQ #NPC #development #zebrafish #transcriptionfactors #nucleartransport https://t.co/uniGb5DMt4
-
-
Mashup Score: 0What Is Niemann-Pick Disease Type C (NPC)? - 3 year(s) ago
Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.
Source: CheckRareCategories: Latest Headlines, Rare DiseaseTweet-
Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d
-
-
Mashup Score: 0What Is Niemann-Pick Disease Type C (NPC)? - 3 year(s) ago
Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d
-
-
Mashup Score: 0
Dr Marc Patterson, MD discusses 24-month interim results from an open-label extension of the phase 2/3 NPC-002 study.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc C. Patterson, MD at Mayo Clinic discusses 24-month interim results from the phase 2/3 NPC-002 study of arimoclomol in Niemann-Pick disease type C #NPC @MayoClinic @MayoClinicHS @NPCFund @NiemannPickUK @NiemannPickOz #Niemann-Pick https://t.co/JITXyhBMjL
-
-
Mashup Score: 0What Is Niemann-Pick Disease Type C (NPC)? - 3 year(s) ago
Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of tislelizumab to standard #chemo continues to show improvement in progression-free survival compared with #chemotherapy alone in patients with recurrent/metastatic #nasopharyngealcancer: https://t.co/BupUZYJrSV #NPC https://t.co/xJlMnCdTml
-
-
Mashup Score: 0
Dr Marc Patterson, MD discusses 24-month interim results from an open-label extension of the phase 2/3 NPC-002 study.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc C. Patterson, MD at Mayo Clinic discusses 24-month interim results from the phase 2/3 NPC-002 study of arimoclomol in Niemann-Pick disease type C #NPC @MayoClinic @MayoClinicHS @NPCFund @NiemannPickUK @NiemannPickOz #Niemann-Pick https://t.co/JITXyhBMjL
-
Randomized phase II study @TheLancetOncol shows that adding bevacizumab to pembrolizumab in previously treated nasopharygeal carcinoma improves RR (58.3% vs 12.5%) and significantly increased PFS to 13.8m from 1.6m: HR 0.25! #NPC https://t.co/B9Kr0DrPuu